Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth

Preterm Birth Clinical Trial

— Pretermbirth  

Official title:

The Effect of Screening and Treatment of Asymptomatic Bacteriuria Every Trimester During Pregnancy on Incidence of Preterm Birth in Harare, Zimbabwe

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03274960
• Other study ID #: 127/16/JREC
• Status: Completed
• Phase: N/A
• Start date: February 23, 2017
• Est. completion date: December 30, 2020

Study information

• Verified date: May 2023
• Source: University of Zimbabwe
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is evaluating whether screening of a pregnant woman for asymptomatic bacteriuria in each trimester for early detection and treatment of bacteriuria will reduce the incidence of preterm birth in Harare.

Description:

Asymptomatic bacteriuria is common in pregnancy. If the disease is not detected early in pregnancy and treated it often progresses to an acute symptomatic disease, pyelonephritis which is associated with adverse pregnancy outcomes including preterm birth.

It is recommended that every woman be screened for asymptomatic bacteriuria by urine culture test at initial antenatal care visit so that the disease is if identified is treated early to prevent preventable complications of the disease in pregnancy. Culture test is expensive and therefore unavailable at several primary care settings especially in low resource settings where majority of pregnant women register and visit for antenatal care. In Zimbabwe antenatal care at primary care clinics is not including screening for asymptomatic bacteriuria. Majority who present with symptoms are empirically treated.

In this study the Griess nitrite test, an effective inexpensive screening test for asymptomatic bacteriuria is used. the test detects nitrite in urine which is associated with presence of nitrate reducing uropathogens, commonly the gram negative bacteria. All the positive samples will then be further tested by culture for bacteria identification, quantification and antibiotic sensitivity. A Randomized controlled trial research design is being used. participants are randomly allocated to intervention group or control group. Urine samples will be collected and tested 3 times for each recruited participant in the intervention arm. treatment will be initiated for positive result according to sensitivity test. Control group will only be subjected to routine existing antenatal care.

Participants will be recruited before 22 weeks gestation and followed on for second contact by 28 weeks and third contact by 36 weeks. Follow up will be stopped on delivery for noting gestation at delivery, whether preterm or term.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 480
• Est. completion date: December 30, 2020
• Est. primary completion date: January 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Pregnant women registering at study site.

• Woman is able to identify her date of last menstrual period.

• Gestation of pregnancy is between 6 and 22 weeks.

• Woman is asymptomatic for bacteriuria

• Woman voluntarily signs the consent form

Exclusion Criteria:

• Pregnant woman ill and unwell

• Pregnant woman unwilling to sign consent form

• Woman who had antibiotic treatment 2 weeks before recruitment

• Woman on long term antibiotic treatment

• Woman who fails to identify date of last menstrual period

• Woman symptomatic for urinary tract infection

Related Conditions & MeSH terms

• Asymptomatic Bacteriuria in Pregnancy
• Bacteriuria
• Premature Birth
• Preterm Birth

Intervention

Combination Product:
• Griess,
Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.

Locations

Country	Name	City	State
Zimbabwe	University of Zimbabwe	Harare	Metropolitan

Sponsors (1)

Lead Sponsor	Collaborator
University of Zimbabwe

Country where clinical trial is conducted

Zimbabwe, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preterm birth	Preterm birth will be delivery of a baby before 37 complete weeks of gestation from the first date of last menstrual period. It will be sub-categorized as extremely preterm (<28 weeks), very preterm (28 to <32 weeks) and moderate to late preterm (32 to <37 weeks).	Preterm birth will be calculated as gestation at birth of baby using date of birth and the first date of last menstrual period.
Secondary	symptomatic bacteriuria	Noted from history of urinary tract symptoms which include pain on micturition, fever, blood in urine, increased urine frequency, foul smelling urine and cloudy urine.	The symptoms will be noted at interviews at follow up after every 6 to 8 weeks from previous contact.
Secondary	Isolated uropathogen	All isolated bacterial species from urine sample identified from culture test. These are bacteria identified to be responsible for asymptomatic bacteriuria.	These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening.
Secondary	Antibiotic sensitivity	from urine culture results identified antibiotics sensitive for treatment of isolated bacteria will be noted.	These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening
Secondary	Gestation at birth	Gestation is the calculated total number of weeks from first date of last menstrual period to the date of delivery.	Gestation will be calculated at delivery of baby.